16:21:35 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
ArcticZymes Technologies är verksamma inom bioteknik. Bolaget specialiserar sig inom forskning och utveckling av läkemedel för behandling av sjukdomar som belastar immunsystemet. Störst inriktning återfinns inom utveckling av glukaner, framtagande av immunstimulerande medel, samt analys av enzymer. Visionen är att testa och utveckla medicinen för att sedan föra vidare dessa i användning för olika RNA och DNA processer. Bolaget gick tidigare under namnet Biotec Pharmacon och har sitt huvudkontor i Tromsö.

Kalender

2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-20 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-01-28 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning AZT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2020-01-06 Extra Bolagsstämma 2020
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-16 Ordinarie utdelning AZT 0.00 NOK
2019-05-15 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-10-18 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-09 Ordinarie utdelning AZT 0.00 NOK
2018-05-07 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-01 Bokslutskommuniké 2017
2017-10-19 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning AZT 0.00 NOK
2017-05-11 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-02 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning AZT 0.00 NOK
2016-05-11 Årsstämma 2016
2016-04-19 Kvartalsrapport 2016-Q1
2016-02-11 Bokslutskommuniké 2015
2016-02-11 Kapitalmarknadsdag 2016
2015-11-03 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning AZT 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-05 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-11-05 Kvartalsrapport 2014-Q3
2014-08-13 Kvartalsrapport 2014-Q2
2014-05-15 Ordinarie utdelning AZT 0.00 NOK
2014-05-14 Årsstämma 2014
2014-04-30 Kvartalsrapport 2014-Q1
2014-02-14 Bokslutskommuniké 2013
2013-11-01 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-05-28 Ordinarie utdelning
2013-05-27 Årsstämma 2013
2013-05-07 Kvartalsrapport 2013-Q1
2013-02-01 Extra Bolagsstämma 2013
2013-01-07 Bokslutskommuniké 2012
2012-11-06 Kvartalsrapport 2012-Q3
2012-08-10 Kvartalsrapport 2012-Q2
2012-05-07 Kvartalsrapport 2012-Q1
2012-05-07 Årsstämma 2012
2012-05-07 Ordinarie utdelning AZT 0.00 NOK
2012-02-21 Bokslutskommuniké 2011
2011-11-08 Kvartalsrapport 2011-Q3
2011-08-10 Kvartalsrapport 2011-Q2
2011-05-13 Kvartalsrapport 2011-Q1
2011-05-13 Årsstämma 2011
2011-05-12 Ordinarie utdelning
2011-02-17 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-10 Kvartalsrapport 2010-Q2
2010-05-11 Kvartalsrapport 2010-Q1
2010-05-04 Årsstämma 2010
2010-03-03 Bokslutskommuniké 2009
2020-06-17 08:41:40

Tromsø, Norway, 17. June 2020 - Biotec Pharmacon (OSE: BIOTEC) announces it has officially rebranded to ArcticZymes Technologies.

As previously announced and decided by the Annual General Meeting, Biotec Pharmacon ASA has formally changed its name to ArcticZymes Technologies ASA. The new name is formally registered with Brønnøysundregistrene and will trade under the new ticker "AZT" over the next days.

The name change will also coincide with the unveiling of a new brand identity, a new corporate logo and an updated website (Arcticzymes.com)

The company has undergone a significant transformation over the last year with the ArcticZymes subsidiary representing the core business and profitable part of the company. The new brand reflects the company's future identity and strategy to focus on growing its enzymes business via a combination of organic and inorganic initiatives. Longer-term, the company has ambitions to expand into other technologies beyond enzymes.

ArcticZymes is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, In vitro Diagnostics (IVD) and molecular research kit products. The success of the enzymes business has been a result of forging long-term commercial partnerships with its customers as a reliable and trusted supplier. Hence, incorporating ArcticZymes into the new corporate brand name is instrumental in recognizing the strong and positive brand positioning the company has achieved in the market.

The two subsidiaries, ArcticZymes AS and Biotec BetaGlucans AS will remain. However, the future direction and activities of the group will be very different than earlier with the enzyme business being at the forefront.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes Technologies has arrived and the company enters a new era. Our future is all about enzymes. With this, the company needed a new image and identity that reflects its foundations and recognizes what is core at driving the future value of the business. I trust our customers, partners and investors are as inspired as us about embarking on a new chapter in the company's history."

-ENDS-

For more information, please contact:

ArcticZymes
Technologies
Jethro Tel: +47 46 85 91 46Email: Jethro.holter@arcticzymes.com
Holter, CEO
Børge Tel: +47 95 29 01 87Email: borge.sorvoll@arcticzymes.com
Sørvoll, CFO

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on premium and novel enzyme as well as immunomodulating beta-glucan technology.

The ArcticZymes Technologies Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsø to offer niche and high-tech products in several biotech segments.

ArcticZymes represents its core business where it develops, manufactures and commercializes novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans represents a non-core business where it produces and markets immunomodulating beta-glucans addressing several market areas.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.arcticzymes.com.